Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The price of ImmunityBio Inc (NASDAQ: IBRX) closed at $2.47 in the last session%, Up $1.23% from day before closing price of $2.44. In other words, the price has increased by $1.23 from its previous closing price. On the day, 9.02 million shares were traded. IBRX stock price reached its highest trading level at $2.6353 during the session, while it also had its lowest trading level at $2.46.
Ratios:
We take a closer look at IBRX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.98 and its Current Ratio is at 4.11.
On March 06, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $8.
On January 10, 2025, BTIG Research started tracking the stock assigning a Buy rating and target price of $6.BTIG Research initiated its Buy rating on January 10, 2025, with a $6 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IBRX now has a Market Capitalization of 2334779904 and an Enterprise Value of 3024416000. For the stock, the TTM Price-to-Sale (P/S) ratio is 41.25. Its current Enterprise Value per Revenue stands at 53.435 whereas that against EBITDA is -11.24.
Stock Price History:
The Beta on a monthly basis for IBRX is 0.18, which has changed by -0.3430851 over the last 52 weeks, in comparison to a change of 0.17279088 over the same period for the S&P500. Over the past 52 weeks, IBRX has reached a high of $7.48, while it has fallen to a 52-week low of $1.83. The 50-Day Moving Average of the stock is -10.87%, while the 200-Day Moving Average is calculated to be -22.74%.
Shares Statistics:
According to the various share statistics, IBRX traded on average about 8.65M shares per day over the past 3-months and 6774190 shares per day over the past 10 days. A total of 915.63M shares are outstanding, with a floating share count of 98.33M. Insiders hold about 89.60% of the company’s shares, while institutions hold 8.79% stake in the company. Shares short for IBRX as of 1753920000 were 77068923 with a Short Ratio of 8.90, compared to 1751241600 on 76962373. Therefore, it implies a Short% of Shares Outstanding of 77068923 and a Short% of Float of 26.479998.
Earnings Estimates
A comprehensive evaluation of ImmunityBio Inc (IBRX) is underway, with the input of 2.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.12, with high estimates of -$0.1 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.44 and -$0.51 for the fiscal current year, implying an average EPS of -$0.47. EPS for the following year is -$0.26, with 2.0 analysts recommending between -$0.23 and -$0.29.
Revenue Estimates
According to 5 analysts, the current quarter’s revenue is expected to be $31.88M. It ranges from a high estimate of $38.11M to a low estimate of $27.5M. As of the current estimate, ImmunityBio Inc’s year-ago sales were $6.11MFor the next quarter, 5 analysts are estimating revenue of $35.29M. There is a high estimate of $47.64M for the next quarter, whereas the lowest estimate is $30M.
A total of 5 analysts have provided revenue estimates for IBRX’s current fiscal year. The highest revenue estimate was $128.7M, while the lowest revenue estimate was $100.44M, resulting in an average revenue estimate of $110.16M. In the same quarter a year ago, actual revenue was $14.74MBased on 5 analysts’ estimates, the company’s revenue will be $239.6M in the next fiscal year. The high estimate is $336.27M and the low estimate is $140.83M.
